Advantages of the Molecular Structure of Aflibercept

Opinion
Video

Panelists discuss how aflibercept’s molecular structure contributes to its clinical efficacy as a standard treatment for retinal vascular diseases.

Video content above is prompted by the following:

  • Aflibercept 2 mg is considered the standard of care for retinal vascular diseases. Can you briefly explain the structure of the aflibercept molecule and its significance?
Recent Videos
3 experts are featured in this series.
Vikas Chopra at AAO 2024: Advancements in MIGS are transforming patient care
AAO 2024: Bonnie An Henderson, MD, talks about advancing medical education with AI, robotics, and diverse learning methods
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Related Content
A person holds an Ozempic injector pen. Image credit: ©alones – stock.adobe.com

European Medicines Agency will assess semaglutide for link to NAION

Hattie Hayes
December 20th 2024
Article

The Danish Medicines Agency requested the EMA's Pharmacovigilance Risk Assessment Committee review reports on the vision-threatening condition

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

A doctor looks at a patient's chest x-ray. Image credit: ©Chinnapong – stock.adobe.com

Ocular tuberculosis and relapse rates for recurrence of uveitis

Lynda Charters
November 26th 2024
Article

Uveitic relapses primarily manifest as anterior uveitis, the authors said

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

Bottles of essential oils are placed next to an essential oil aromatherapy diffuser in a calm, warm, spa-like environment. Image credit: ©Botamochy – stock.adobe.com

Adding aromatherapy to recovery protocol may decrease postoperative anxiety and pain

Lynda Charters
November 8th 2024
Article

Following oculoplastic surgery, patients who underwent aromatherapy had shorter stays in the post-anesthesia care unit

Light therapy: Potential treatment for dry AMD

Light therapy: Potential treatment for dry AMD

Lynda Charters
October 18th 2024
Article

Non-invasive, painless laser can reduce risk of vision loss

© 2024 MJH Life Sciences

All rights reserved.